A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death.
Mannion J, Gifford V, Bellenie B, Fernando W, Ramos Garcia L, Wilson R, John SW, Udainiya S, Patin EC, Tiu C, Smith A, Goicoechea M, Craxton A, Moraes de Vasconcelos N, Guppy N, Cheung KJ, Cundy NJ, Pierrat O, Brennan A, Roumeliotis TI, Benstead-Hume G, Alexander J, Muirhead G, Layzell S, Lyu W, Roulstone V, Allen M, Baldock H, Legrand A, Gabel F, Serrano-Aparicio N, Starling C, Guo H, Upton J, Gyrd-Hansen M, MacFarlane M, Seddon B, Raynaud F, Roxanis I, Harrington K, Haider S, Choudhary JS, Hoelder S, Tenev T, Meier P.
Mannion J, et al. Among authors: ramos garcia l.
Immunity. 2024 Jul 9;57(7):1514-1532.e15. doi: 10.1016/j.immuni.2024.04.025. Epub 2024 May 23.
Immunity. 2024.
PMID: 38788712
Free article.